Zaitseva Marina, Peden Keith, Golding Hana
Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA.
Biochim Biophys Acta. 2003 Jul 11;1614(1):51-61. doi: 10.1016/s0005-2736(03)00162-7.
The human immunodeficiency virus (HIV) envelope glycoprotein forms trimers on the virion surface, with each monomer consisting of two subunits, gp120 and gp41. The gp120 envelope component binds to CD4 on target cells and undergoes conformational changes that allow gp120 to interact with certain G-protein-coupled receptors (GPCRs) on the same target membranes. The GPCRs that function as HIV coreceptors were found to be chemokine receptors. The primary coreceptors are CCR5 and CXCR4, but several other chemokine receptors were identified as "minor coreceptors", indicating their ability support entry of some HIV strains in tissue cultures. Formation of the tri-molecular complexes stabilizes virus binding and triggers a series of conformational changes in gp41 that facilitate membrane fusion and viral cell entry. Concerted efforts are underway to decipher the specific interactions between gp120/CD4, gp120/coreceptors, and their contributions to the subsequent membrane fusion process. It is hoped that some of the transient conformational intermediates in gp120 and gp41 would serve as targets for entry inhibitors. In addition, the CD4 and coreceptors are primary targets for several classes of inhibitors currently under testing. Our review summarizes the current knowledge on the interactions of HIV gp120 with its receptor and coreceptors, and the important properties of the chemokine receptors and their regulation in primary target cells. We also summarize the classes of coreceptor inhibitors under development.
人类免疫缺陷病毒(HIV)包膜糖蛋白在病毒粒子表面形成三聚体,每个单体由两个亚基gp120和gp41组成。gp120包膜成分与靶细胞上的CD4结合,并发生构象变化,使gp120能够与同一靶细胞膜上的某些G蛋白偶联受体(GPCR)相互作用。被发现作为HIV共受体发挥作用的GPCR是趋化因子受体。主要共受体是CCR5和CXCR4,但其他几种趋化因子受体被鉴定为“次要共受体”,这表明它们能够支持某些HIV毒株在组织培养中的进入。三分子复合物的形成稳定了病毒结合,并引发gp41中的一系列构象变化,促进膜融合和病毒进入细胞。目前正在齐心协力破译gp120/CD4、gp120/共受体之间的特异性相互作用,以及它们对随后膜融合过程的贡献。人们希望gp120和gp41中的一些瞬时构象中间体将成为进入抑制剂的靶点。此外,CD4和共受体是目前正在测试的几类抑制剂的主要靶点。我们的综述总结了目前关于HIV gp120与其受体和共受体相互作用的知识,以及趋化因子受体的重要特性及其在主要靶细胞中的调节。我们还总结了正在开发的共受体抑制剂的类别。